HeartBeam adds two new U.S. patents

HeartBeam (BEAT) announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam’s groundbreaking innovations and further solidify the Company’s intellectual property footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians. The first patent protects IP around HeartBeam’s credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. Data from the VALID-ECG pivotal study supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025. The second patent protects HeartBeam’s rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam’s credit card-sized device, enabling synthesis of a 12-lead ECG.